GH
HEALTHCAREGuardant Health Inc
$92.25+2.73 (+3.05%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GH Today?
No stock-specific AI insight has been generated for GH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$36.36$120.74
$92.25
Fundamentals
Market Cap$12.2B
P/E Ratio—
EPS$-3.32
Dividend Yield—
Dividend / Share—
ROE-45.8%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding132.6M
GH News
23 articles- Guardant Health : Q1 2026 Earnings Callmarketscreener.com·May 9, 2026
- Guardant Health CMO resignsMSN·May 9, 2026
- Guardant Health (GH) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Guardant Health Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 7, 2026
- Guardant Health (GH) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock SoarsYahoo Finance·May 7, 2026
- Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceYahoo Finance·May 7, 2026
- Why The Dip In TEM Stock Is A Buying WindowTrefis·May 6, 2026
- Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- The Bull Case For Guardant Health (GH) Could Change Following New ESR1 Liquid Biopsy CDx Approval – Learn WhyYahoo Finance·May 5, 2026
- Repligen (RGEN) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·May 5, 2026
- Does Guardant Health (GH) Have Long-Runway for Growth?Yahoo Finance·May 4, 2026
- Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 MutationsYahoo Finance·May 4, 2026
- Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·Apr 30, 2026
- Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformYahoo Finance·Apr 30, 2026
- Guardant Health to Participate in Upcoming Investor ConferencesYahoo Finance·Apr 29, 2026
- Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 16, 2026
- OS Therapies Appoints Craig Eagle, MD as Strategic AdvisorYahoo Finance·Apr 8, 2026
- Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To KnowYahoo Finance·Apr 6, 2026
- Guardant Health (GH) Valuation Check After Strong 1 Year Return And Recent 90 Day PullbackYahoo Finance·Apr 4, 2026
- 1 Healthcare Stock with Exciting Potential and 2 Facing HeadwindsYahoo Finance·Apr 2, 2026
- Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level OutlookGlobeNewswire Inc.·Mar 30, 2026
All 23 articles loaded
Price Data
Open$0.00
Previous Close$89.52
Day High$0.00
Day Low$0.00
52 Week High$120.74
52 Week Low$36.36
52-Week Range
$36.36$120.74
$92.25
Fundamentals
Market Cap$12.2B
P/E Ratio—
EPS$-3.32
Dividend Yield—
Dividend / Share—
ROE-45.8%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding132.6M
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—